Oocyte Collection System Market Global Report 2026

The oocyte collection system market size has grown rapidly in recent years. It will grow from $6.17 billion in 2025 to $7.17 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth during the historic period can be attributed to growing demand for assisted reproductive technologies, increasing infertility treatment procedures, rising adoption of minimally invasive fertility procedures, expansion of fertility clinic infrastructure, and increasing awareness of reproductive health services.

The oocyte collection system market size is expected to see rapid growth in the next few years. It will grow to $12.91 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth during the forecast period can be attributed to rising demand for advanced oocyte retrieval systems, increasing investment in fertility treatment infrastructure, growing adoption of automated aspiration technologies, expanding access to assisted reproductive services, and greater emphasis on improving oocyte retrieval efficiency. Major trends during the forecast period include increasing adoption of minimally invasive oocyte retrieval procedures, rising demand for precision follicular aspiration systems, greater focus on sterile single-use collection devices, expansion of temperature-controlled sample handling solutions, and increasing preference for integrated oocyte retrieval workflows.

The increasing global infertility rates are expected to propel the growth of the oocyte collection system market going forward. Infertility refers to the inability to achieve pregnancy after a prolonged period of regular, unprotected intercourse, and its prevalence is increasing across both developed and developing regions. Infertility rates are rising due to delayed parenthood, as individuals are increasingly choosing to have children at older ages, while natural fertility declines with age, particularly among women, due to reductions in both the quantity and quality of eggs, making conception more difficult. Oocyte collection systems are used to facilitate the safe and efficient retrieval of mature eggs from a woman’s ovaries during assisted reproductive procedures such as IVF, thereby improving the chances of successful fertilization and conception among individuals affected by declining fertility rates. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 17.5% of the adult population, or about 1 in 6 people globally, experience infertility, highlighting the need to improve access to affordable, high-quality fertility care for affected individuals. Therefore, the increasing global infertility rates are driving the growth of the oocyte collection system market.

Major companies operating in the oocyte collection system market are concentrating on innovations in aspiration needle design, including enhanced echogenic surface technology, to help clinicians perform oocyte retrieval with greater precision and lower procedural risk. Enhanced echogenic surface technology refers to a needle surface treatment that improves the visibility of the needle tip under ultrasound guidance, enabling clinicians to track its position throughout the retrieval procedure. For instance, in November 2025, Rocket Medical plc, a UK-based medical device company, introduced the Embryon SX single lumen aspiration needle to improve oocyte retrieval accuracy and ultrasound-guided visualization during IVF procedures while enhancing procedural control and reducing patient trauma. The needle incorporates a spiral echo bevel design for high-resolution ultrasound definition, a shaped finger grip with a bevel marker to support procedural control, and an Oxford tubing set with a clear silicone bung for secure connection to the aspiration line.

In October 2023, Hamilton Thorne Ltd., a Canada-based precision instruments and assisted reproductive technology (ART) company, acquired Gynetics Medical Products N.V. for an undisclosed amount. Through this acquisition, Hamilton Thorne Ltd. aims to strengthen and broaden its consumables and clinical product portfolio in the global IVF and assisted reproductive technology market by adding high-quality, recurring-revenue IVF consumables, expanding its presence in the European ART sector, and leveraging synergies between its existing distribution channels and Gynetics’ established embryo transfer and ovum pick-up product lines to support broader international commercialization and long-term revenue growth in fertility care solutions. Gynetics Medical Products N.V. is a Belgium-based medical device company that specializes in designing and manufacturing oocyte collection systems.

Major companies operating in the oocyte collection system market are CooperSurgical Inc., Vitrolife AB, Nexpring Health, Genea Biomedx, Esco Medical ApS, Rocket Medical plc, BIRR BioSciences B.V., SparMED ApS, Laboratoire CCD S.A.S., Labotect GmbH, MedGyn Products Inc., Vitromed GmbH, RI.MOS S.r.l., Gynotec B.V.

North America was the dominant region in the oocyte collection system market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the oocyte collection system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oocyte collection system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.